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Summary
Older adult patients (≥60 years) with acute myeloid leukaemia (AML) are
generally considered to be poor-risk and there is limited information avail-
able regarding risk stratification based on molecular characterization in this
age group, particularly for the double-mutant CEBPA (CEBPADM) geno-
type. To investigate whether a molecular favourable-risk genotype can be
identified, we investigated CEBPA, NPM1 and FLT3 status and prognostic
impact in a cohort of 301 patients aged 60 years or more with intermedi-
ate-risk cytogenetics, all treated intensively. Overall survival (OS) at 1 year
was highest in the 12 patients (4%) that were CEBPADM compared to the
76 (28%) with a mutant NPM1 and wild-type FLT3 (NPM1MUTFLT3WT)
genotype or all other patients (75%, 54%, 33% respectively), with median
survival 152, 136 and 66 months, although the benefit was short-term
(OS at 3 years 17%, 29%, 12% respectively). Combination of the CEB-
PADM and NPM1MUTFLT3WT genotype patients defined a molecular group
with favourable prognosis (P < 00001 in multivariate analysis), with 57%
of patients alive at 1 year compared to 33% for all other patients. Knowl-
edge of genotype in older cytogenetically intermediate-risk patients might
influence therapy decisions.
Keywords: acute myeloid leukaemia, molecular prognostication, CEBPA
genotype, NPM1 and FLT3 genotype.
In recent decades there have been considerable improvements
in the long-term outlook for younger adult patients with
acute myeloid leukaemia (AML) (Burnett et al, 2011). Cur-
rent therapy is risk-adapted, based predominantly on cytoge-
netics and molecular characterization (Dohner et al, 2010;
Dohner & Gaidzik, 2011; Ofran & Rowe, 2013), and consoli-
dation of first remission by allogeneic transplantation is not
usually considered in patients with either good-risk cytoge-
netics or a favourable mutation profile, defined as either
mutant for nucleophosmin 1 and lacking a fms-like tyrosine
kinase 3 internal tandem duplication (NPM1MUTFLT3WT) or
double mutant for CCAAT/enhancer binding protein-a
(CEBPADM) (Cornelissen et al, 2012; O’Donnell et al, 2012).
These two mutational categories are almost totally mutually
exclusive (Green et al, 2010). In our study of younger
patients, the presence of an NPM1MUTFLT3WT genotype was
associated with a higher complete remission (CR) rate and a
lower relapse rate, both contributing to improved survival
(Gale et al, 2008). The presence of a CEBPADM genotype was
associated with a non-significantly higher CR rate and a sig-
nificantly lower relapse rate, leading to improved long-term
survival (Green et al, 2010).
However, the median age of AML at diagnosis approxi-
mates 70 years (Derolf et al, 2009), so that the majority of
patients are considered to be elderly (≥60 years), and the
improvements seen in the prognosis of younger patients have
not been matched by improvements in this older age group
(Derolf et al, 2009; Burnett et al, 2011; Thein et al, 2013).
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This is attributable to both biological factors (e.g. co-mor-
bidities, poor performance status, pharmacokinetics and
pharmacodynamics) and disease-related factors (e.g. adverse
cytogenetic and molecular aberrations, multidrug resistance
and antecedent haematological disorders) (Pollyea et al,
2011; Ossenkoppele & Lowenberg, 2015).
There is limited information concerning risk stratification
in the older compared to younger patients, partly because all
older patients have been considered as poor-risk. The reasons
for risk stratification in the older age group, however, are
different from those in younger patients. In the older patient
fit enough to receive intensive therapy, there is a growing
consensus that more intensive therapy, similar to that used
in younger patients, results in prolonged survival (Derolf
et al, 2009; Oran & Weisdorf, 2012), and the quality of life is
probably no worse than in those receiving best supportive
care or non-intensive therapy (Alibhai et al, 2015). This does
not imply that living with AML is not extremely difficult for
older patients, and some informed patients might choose not
to receive life-extending therapy. One of the factors to be
considered in making this decision is how long patients are
likely to live if they elect to receive intensive therapy, and
prognostic stratification in the elderly is clearly relevant to
this issue.
There is some data suggesting a better outcome, at least in
the short- to medium-term, in those older patients with
intermediate-risk (IR) cytogenetics and an NPM1MUT or
NPM1MUTFLT3WT genotype, although this largely manifests
as increased duration of survival rather than cure (Buchner
et al, 2009; Becker et al, 2010; Lazenby et al, 2014), and may
be limited to those ≤65 years of age (Ostronoff et al, 2015).
There is very little data on the impact of CEBPADM specifi-
cally in the older age group. We have therefore determined
the impact on survival of the NPM1, FLT3 and CEBPA
mutation status in a cohort of 301 patients aged 60 years or
more with IR cytogenetics who received intensive therapy.
We first examined the impact of the presence of a CEBPADM
genotype and then considered the outcome of the combined
NPM1MUTFLT3WT and CEBPADM subgroup (considered as
the favourable mutational profile in younger patients) com-
pared to those with any other genotype.
Methods
Patients and mutation analysis
Genomic DNA was available from diagnostic samples of
301 (45%) of the 662 patients aged ≥60 years with IR cyto-
genetics and entered on the UK Medical Research Council
(MRC) AML11 trial between 1990 and 1998. Median age
was 67 years (range, 60–85). Compared to the 361 patients
with IR cytogenetics that were not included in the study,
there was no difference in age, sex or type of leukaemia (de
novo/secondary), CR rate or overall survival (OS), but
patients studied were more likely to have a higher present-
ing white blood cell count (WBC) (Table SI). Ethical
approval for the trial was obtained from participating insti-
tution’s ethics review committees and patients gave
informed consent. FLT3, NPM1 and CEBPA screening were
performed as previously described (Gale et al, 2008; Green
et al, 2010).
Therapy, clinical endpoints and statistical methods
Details of the trial protocol have been published elsewhere
(Goldstone et al, 2001). CR was defined as a normocellular
bone marrow (BM) containing <5% blasts and showing evi-
dence of normal maturation of other marrow elements. Per-
sistence of myelodysplastic features did not preclude the
diagnosis of CR. OS was the time from trial entry to death.
For patients achieving CR, relapse-free survival (RFS) was
the time from the date of first CR to an event (death in first
CR or relapse) and cumulative incidence of relapse (CIR)
was the incidence of relapse after CR, with death in CR as a
competing risk.
Mantel-Haenszel and chi-squared tests were used to test
for differences in demographic and clinical data by genotype.
Kaplan–Meier curves were constructed for survival data and
compared by means of the log-rank test. Surviving patients
were censored on 9 August, 2010, with follow-up complete
for 98% of patients. Median follow-up for survival was
161 years (range, 137–195 years). Multivariate Cox models
were used to analyse CIR and OS, adjusting for age, sec-
ondary leukaemia, WBC, performance status and molecular
genotype. Models were fitted using forward selection, with
variables added to the model if they had a P value, derived
using the deviance statistic, of <005. Odds ratios (OR) or
hazard ratios (HR) and 95% confidence intervals (CI) are
quoted for endpoints. In all cases a ratio of <1 indicates ben-
efit. All P values are two-tailed.
Results
Patient characteristics according to CEBPA genotype
Details of the cohort studied are shown in Table I. Overall,
28 patients (9%) were CEBPAMUT, 16 (57%; 5% of total
cohort) had a single mutation (CEBPASM) and 12 (43%; 4%)
were CEBPADM (Fig 1, Table SII). All CEBPADM patients
had mutations that would be predicted to lead to complete
loss of normal C/EBP-a activity, with N-terminal mutations
leading to production of the p30 isoform or frameshift or
nonsense mutations leading to a truncated protein and/or C-
terminal mutations disrupting the DNA binding or leucine
zipper domains. There was no significant difference between
CEBPADM, CEBPASM and CEBPAWT patients in age, sex, type
of leukaemia, WBC and incidence of either FLT3ITD or
NPM1MUT, although it should be noted that no patient with
a CEBPADM had the NPM1MUTFLT3WT genotype (P = 002)
(Table I).
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Response to therapy and outcome of patients with
CEBPA mutations
There was no evidence of a benefit in CEBPASM patients,
where response to therapy and outcome were either the same
or worse than CEBPAWT patients (Table II). CEBPADM
patients had a higher CR rate than CEBPAWT patients (75%
vs. 59%). Although a relatively large difference, this was not
significant in multivariate analysis adjusting for baseline
characteristics (OR = 033, CI = 008–138; P = 012), which
is not unexpected as the number of such cases is small
Table I. Characteristics of the patients studied according to CEBPA genotype.
Parameter CEBPAWT (n = 273) CEBPASM (n = 16) CEBPADM (n = 12) WT versus Single versus Double
Age, years 019†
60–64 92 (34%) 6 (38%) 7 (58%)
65–69 96 (35%) 5 (31%) 3 (25%)
≥70 85 (31%) 5 (31%) 2 (17%)
Median (range) 67 (60–85) 66 (60–75) 63 (60–74)
Sex 05*
Female 117 (43%) 8 (50%) 6 (50%)
Male 156 (57%) 8 (50%) 6 (50%)
Performance Status 08*
WHO 0 105 (38%) 8 (50%) 4 (33%)
WHO 1 121 (44%) 5 (31%) 7 (58%)
WHO 2 18 (7%) 1 (6%) 0
WHO 3 23 (8%) 1 (6%) 1 (8%)
WHO 4 6 (2%) 1 (6%) 0
Diagnosis 05*
De Novo 202 (74%) 12 (75%) 10 (83%)
Secondary 71 (26%) 4 (25%) 2 (17%)
WBC, 9109/l 014†
0–99 90 (33%) 5 (31%) 2 (17%)
10–499 91 (34%) 4 (25%) 6 (50%)
50–999 53 (20%) 3 (19%) 1 (8%)
≥100 37 (14%) 4 (25%) 3 (25%)
Median (range) 266 (03–5130) 305 (18–349) 402 (42–301)
FLT3ITD 08*
WT 206 (75%) 9 (56%) 11 (92%)
Mutant 67 (25%) 7 (44%) 1 (8%)
NPM1MUT 03*
WT 157 (58%) 5 (31%) 11 (92%)
Mutant 116 (42%) 11 (69%) 1 (8%)
NPM1MUTFLT3WT 76 (28%) 7 (44%) 0 (0%) 002‡
Other 197 (72%) 9 (56%) 12 (100%)
DM, double mutant; SM, single mutant; ITD, internal tandem duplication; MUT, mutant; WT, wild-type; WBC, white blood cell count; WHO,
World Health Organization.
*Test for trend.
†Spearman correlation.
‡Fisher’s exact test.
Fig 1. Location and type of mutation detected
in CEBPA-single mutant and CEBPA-double
mutant patients. Amino acids (AA) encoding
the transactivation domains (TAD1 and
TAD2), DNA-binding domain (DBD) and leu-
cine zipper domain (LZD) and the ATG start
site for the p30 isoform are indicated.
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(n = 12) (Table II). CIR was lower in the CEBPADM patients
compared to the CEBPAWT patients, being 44% vs. 55%,
respectively, at 1 year and 67% vs. 73% at 3 years (Fig 2A),
but again this did not achieve statistical significance (P = 04
for CEBPADM versus all others). Short-term survival was
improved for CEBPADM patients (median 471 d for
CEBPADM and 248 d for CEBPAWT), although the benefit
was lost by 3 years when the OS was the same (17% vs.
18%) (Fig 2B). In multivariate analysis, there was a trend for
a better OS in the CEBPADM patients when compared to
other patients (HR = 057, CI = 031–108; P = 008).
Comparison of response to therapy and outcome in
patients with CEBPADM, NPM1MUTFLT3WT and Other
genotypes
Although the CEBPADM genotype appeared to be associated
with only a limited benefit in outcome, the above analysis is
likely to be influenced by the presence of good-risk
NPM1MUTFLT3WT patients in the non-CEBPADM group,
which would attenuate any difference between CEBPADM
patients and those with a poor-risk genotype. Overall, 83T
ab
le
II
.
O
u
tc
o
m
e
d
at
a
ac
co
rd
in
g
to
C
E
B
P
A
ge
n
o
ty
p
e.
O
u
tc
o
m
e
C
E
B
P
A
W
T
(n
=
27
3)
C
E
B
P
A
S
M
(n
=
16
)
C
E
B
P
A
D
M
(n
=
12
)
C
E
B
P
A
W
T
ve
rs
u
s
C
E
B
P
A
S
M
ve
rs
u
s
C
E
B
P
A
D
M
O
R
o
r
H
R
(9
5%
C
I)
,
P
-v
al
u
e
C
E
B
P
A
D
M
ve
rs
u
s
n
o
t
O
R
o
r
H
R
(9
5%
C
I)
,
P
-v
al
u
e
U
n
iv
ar
ia
te
*M
u
lt
iv
ar
ia
te
U
n
iv
ar
ia
te
*M
u
lt
iv
ar
ia
te
C
R
/C
R
i
59
%
56
%
75
%
07
9
(0
46
–1
37
),
P
=
04
07
1
(0
39
–1
27
),
P
=
02
05
1
(0
16
–1
66
),
P
=
03
03
3
(0
08
–1
38
),
P
=
01
2
30
-d
m
o
rt
al
it
y
20
%
25
%
8%
08
2
(0
42
–1
57
),
P
=
05
07
6
(0
38
–1
51
),
P
=
04
05
3
(0
15
–1
84
),
P
=
03
03
5
(0
05
–2
60
),
P
=
03
3-
ye
ar
O
S
18
%
6%
17
%
09
2
(0
71
–1
19
),
P
=
05
08
7
(0
67
–1
13
),
P
=
03
07
5
(0
45
–1
27
),
P
=
03
05
7
(0
31
–1
08
),
P
=
00
8
3-
ye
ar
R
F
S
21
%
11
%
22
%
09
5
(0
69
–1
31
),
P
=
08
09
3
(0
68
–1
29
),
P
=
07
08
3
(0
43
–1
59
),
P
=
06
07
4
(0
36
–1
55
),
P
=
04
3-
ye
ar
C
IR
73
%
89
%
67
%
09
6
(0
68
–1
35
),
P
=
08
09
4
(0
66
–1
34
),
P
=
07
07
5
(0
37
–1
52
),
P
=
04
06
8
(0
29
–1
58
),
P
=
04
95
%
C
I,
95
%
co
n
fi
d
en
ce
in
te
rv
al
s;
C
IR
,
cu
m
u
la
ti
ve
in
ci
d
en
ce
o
f
re
la
p
se
;
C
R
,
co
m
p
le
te
re
m
is
si
o
n
;
C
R
i,
co
m
p
le
te
re
m
is
si
o
n
w
it
h
in
co
m
p
le
te
h
ae
m
at
o
lo
gi
ca
l
re
co
ve
ry
;
D
M
,
d
o
u
b
le
m
u
ta
n
t;
H
R
,
h
az
ar
d
ra
ti
o
;
O
R
,
o
d
d
s
ra
ti
o
;
O
S,
o
ve
ra
ll
su
rv
iv
al
;
R
F
S,
re
la
p
se
-f
re
e
su
rv
iv
al
;
SM
,
si
n
gl
e
m
u
ta
n
t;
W
T
,
w
il
d
-t
yp
e.
*A
d
ju
st
ed
fo
r
ag
e,
se
co
n
d
ar
y
le
u
ka
em
ia
,
w
h
it
e
b
lo
o
d
ce
ll
co
u
n
t,
p
er
fo
rm
an
ce
st
at
u
s,
F
L
T
3
an
d
N
P
M
1
ge
n
o
ty
p
e.
(A)
(B)
Fig 2. Kaplan–Meier curves stratified according to CEBPA genotype.
(A) Cumulative incidence of relapse. (B) Overall survival. WT, wild
type.
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patients (28%) had an NPM1MUTFLT3WT genotype and it
was mutually exclusive with a CEBPADM genotype. We there-
fore divided the patients into three groups,
NPM1MUTFLT3WT patients, CEBPADM patients, and all other
patients (i.e. those with an NPM1WT or NPM1MUTFLT3ITD
genotype), hereafter called ‘Other’ genotypes. The CR rate in
patients with an NPM1MUTFLT3WT genotype was 71% com-
pared to 75% in the CEBPADM patients and 54% in those
with ‘Other’ genotypes (Table III). NPM1MUTFLT3WT or
CEBPADM patients had a lower CIR at 1 year than the
remaining patients (44%, 56% and 62% respectively). How-
ever, this difference was less apparent by 3 years (66%, 67%
and 78% respectively) and, although it was statistically signif-
icant in univariate analysis (P = 001 for the 3-way compar-
ison), it did not retain significance after adjustment for other
factors (P = 03) (Fig 3A). Survival at 1 year was highest in
the CEBPADM group, but this then fell towards the level of
the patients in the ‘Other’ genotype category and showed no
difference by 2 years (Fig 3B). Even so, multivariate analysis
showed that the OS was significantly better in the CEBPADM
patients than in the ‘Other’ genotypic group (HR = 052,
CI = 028–097, P = 004). Similarly, OS was significantly
better in the NPM1MUTFLT3WT group compared to the
‘Other’ genotype group (P < 00001 for univariate analysis;
P = 0002 for multivariate analysis). Median survival was
136, 152 and 66 months, respectively, in the
NPM1MUTFLT3WT, CEBPADM and ‘Other’ groups.
As outcome was broadly comparable for the CEBPADM
and NPM1MUTFLT3WT patients, they were combined into a
favourable-risk group, as in younger patients, together com-
prising 32% of the patients in this study. OS was very signifi-
cantly better in this combined group than the ‘Other’
genotypes group, 57% vs. 33% at 1 year, and 27% vs. 12%
at 3 years (HR = 050, CI = 038–065, P < 00001 in multi-
variate analysis) (Fig 3C). Median survival was 143 months
in the favourable-risk group compared to only 66 months in
the remainder. There was no evidence that survival in the
favourable-risk group differed according to age: OS at
3 years was 30% for the 56 patients (59%) aged >65 years
compared to 23% for those aged <65 years (HR = 092,
CI = 059–144; P = 07) (Fig 3D), median survival 143 and
140 months, respectively.
Discussion
In younger adult AML patients the presence of a CEBPADM
genotype is associated with better response to treatment and
improved long-term outcome (Green et al, 2010; Taskesen
(A)
(B)
(C)
(D)
Fig 3. Kaplan–Meier curves stratified according to CEBPADM and NPM1MUTFLT3WT genotype. (A) Cumulative incidence of relapse and (B)
overall survival in the three genotype groups. (C) Overall survival for the combined favourable-risk CEBPADM and NPM1MUTFLT3WT group com-
pared with all other patients. (D) Overall survival stratified according to age in the favourable-risk group. CEBPA double, CEBPADM genotype;
ITD wt NPM1 mut, NPM1MUTFLT3WT genotype.
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et al, 2011). It is sometimes assumed that this is also true in
older patients (Ossenkoppele & Lowenberg, 2015), but this
has never been formally demonstrated, with such results only
presented within a much wider age range of patients (Ren-
neville et al, 2009; Wouters et al, 2009; Dufour et al, 2010;
Fasan et al, 2014). The study presented here is the first to
report on the impact of a CEBPADM genotype specifically in
patients ≥60 years of age. The incidence of 4% CEBPADM in
the present cohort was similar to the 5% incidence reported
in our study of younger patients with IR cytogenetics (Green
et al, 2010), and is consistent with other studies where age
and double/single mutant status have been given (Dufour
et al, 2010; Marcucci et al, 2012). A CEBPADM genotype was
associated with improved short-term survival that was signif-
icant in multivariate analysis when compared to patients
without either a CEBPADM or NPM1MUTFLT3WT genotype.
It is clear that this improvement is relatively short-lived and
does not equate to a high cure rate.
Older patients with an NPM1MUTFLT3WT genotype have
already been shown to have an improved 1-year OS (Buch-
ner et al, 2009; Lazenby et al, 2014; Ostronoff et al, 2015),
and this was confirmed in the present cohort. The combined
favourable-risk genotypic group reported here, of either a
CEBPADM or an NPM1MUTFLT3WT genotype, accounted for
32% of all the patients investigated, although it must be
acknowledged that this cohort was restricted to patients
deemed fit enough to receive intensive chemotherapy. Even
in this favourable-risk genotypic group only 57% of the
patients were alive at 1 year and the corollary of identifying
a favourable group is that, by default, an unfavourable-risk
group is also identified. In this cohort of patients, of those
without a favourable-risk genotype, nearly 50% had died by
6 months and only 12% were alive at 3 years.
Although the cohort presented here was treated two dec-
ades ago, there has been very little progress in the interven-
ing years in improving outcome in this age group and the
findings are still likely to apply. This disease-related informa-
tion needs to be integrated with other patient-related infor-
mation, including co-morbidities, but for some patients it
may influence the decision of whether or not to receive
intensive therapy. Therefore consideration should be given to
offering molecular screening as part of the diagnostic work-
up for older patients with IR cytogenetics. Nevertheless, even
for the more favourable-risk group, there remains an
undoubted need to develop novel therapeutic strategies for
older patients with AML.
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